Given the unmet medical need and burden associated with genital herpes, the approval of an innovative vaccine is much anticipated. Unfortunately, developing protective herpes simplex virus (HSV) vaccines has been challenging for decades.
However, the wait will continue according to GSK plc's recent announcement.
Another Herpes Vaccine Candidate Flops
Long-Course Chemoradiotherapy Preferred TNT Regimen for Rectal Cancer
LCCRT results in higher two-year organ preservation and lower two-year local regrowth compared with short-course radiotherapy